Loading...
Interactive visualization of Health-Related Quality of Life (HRQOL) outcomes from the MONALEESA-3 study.
Study Design & Arms
Comparison of Ribociclib + Fulvestrant vs. Placebo + Fulvestrant in HR+/HER2- advanced breast cancer.
Time to Definitive Deterioration (TTD)
Comparison of median/mean months to deterioration (≥10%) across key domains. Higher values indicate longer preservation of QOL.
Baseline Global Health Status
Comparison of baseline EORTC QLQ-C30 scores (Mean ± SD). Scores range 0-100.
Hazard Ratios (Time to Deterioration)
Forest plot of Hazard Ratios (HR) extracted from study notes. HR < 1 favors Ribociclib.
Absolute Difference (Intervention - Control)
Positive values indicate Ribociclib group had higher scores/longer time. Negative indicates Placebo was higher.
Metric Summary Heatmap
Overview of all extracted quantitative values.
Appendix: Raw Data
| ID | Metric | Group | Value | Unit | Source |
|---|